10-Q: Upexi Inc. Reports Q1 2025 Results, Revenue Declines Amid Strategic Shift

Upexi Inc. reports a significant decrease in revenue for the quarter ended September 30, 2024, as the company focuses on branded product sales and completes a manufacturing consolidation.

Summary

• Upexi Inc. reported a net loss of $1,625,577 for the three months ended September 30, 2024, compared to a loss of $1,355,388 for the same period in 2023.
• Revenue decreased by 47% to $4,356,515, down from $8,274,690 in the prior year, primarily due to the discontinuation of the recommerce business and the manufacturing consolidation.
• Cost of revenue also decreased by 50% to $1,426,447, reflecting the decline in sales.
• Sales and marketing expenses were reduced by 43% to $1,041,425, as the company focused on core products and reduced agency expenses.
• Distribution costs decreased by 32% to $1,455,725, due to the decline in recommerce revenue.
• General and administrative expenses decreased by 13% to $1,367,690, with further reductions expected.
• Other operating expenses decreased by 71% to $400,393, mainly due to reduced amortization of intangible assets and stock-based compensation.
• Interest expense decreased by 66% to $290,412, due to the elimination of acquisition debt and the sale of VitaMedica.
• The company had a working capital deficit of $2,981,121 as of September 30, 2024, compared to a deficit of $1,235,234 as of June 30, 2024.
• Cash increased to $1,790,391, up from $661,415 at the end of the previous quarter, primarily due to the sale of a building and the collection of proceeds from the sale of E-core.

Sentiment

Score: 4

Explanation: The document presents a mixed picture with significant revenue decline and increased losses, but also positive steps in cost reduction and asset sales. The overall sentiment is cautiously negative due to the financial challenges and material weaknesses in internal controls.

Positives

• The company successfully sold its building for $4,300,000, improving its cash position.
• Upexi received $2,000,000 from the sale of E-core Technology Inc., further bolstering its cash reserves.
• The company has reduced sales and marketing expenses by 43% and distribution costs by 32%, indicating a focus on efficiency.
• General and administrative expenses have decreased by 13%, with further reductions expected.
• Interest expenses have decreased by 66%, due to the elimination of acquisition debt and the sale of VitaMedica.
• Upexi has regained compliance with Nasdaq listing rules, which is a positive step for investor confidence.

Negatives

• Upexi experienced a significant 47% decrease in revenue year-over-year, indicating a substantial impact from the strategic shift.
• The company's net loss increased compared to the same period last year, highlighting ongoing financial challenges.
• Upexi has a working capital deficit of $2,981,121, which could pose liquidity risks.
• The company's manufacturing consolidation impacted sales, indicating potential operational challenges during the transition.

Risks

• The company's strategic shift away from recommerce has resulted in a significant decline in revenue, and the success of the new strategy is not yet fully realized.
• The company has a working capital deficit, which could impact its ability to fund operations and meet debt obligations.
• The company's internal controls over financial reporting have material weaknesses, which could lead to misstatements in financial reports.
• The company is subject to uncertainties related to the regulation of cannabinoids, which could affect the introduction of its products in different markets.
• The company is involved in a dispute with the Depository Trust Company (DTC) regarding the issuance of shares related to the reverse stock split, which could lead to potential dilution.

Future Outlook

The company expects general and administrative expenses to continue to decline, with the most significant declines being realized in periods ending after December 31, 2024. Management estimates that they will have sufficient working capital to fund operations over the next twelve months and meet all debt obligations.

Management Comments

• Management has augmented the overall strategy of the Company to focus on product sales, including the development, production and distribution of branded products.
• Management will continue to reduce overall distribution costs with the consolidation of products and facilities.
• Management expects that general and administrative expenses to continue to decline, with the most significant declines being realized in periods ending after December 31, 2024.

Industry Context

The company's strategic shift away from recommerce and focus on branded products reflects a broader trend in the e-commerce industry towards building proprietary brands and controlling the supply chain. The company's challenges in managing the transition and maintaining revenue highlight the difficulties in executing such a shift.

Comparison to Industry Standards

• Upexi's revenue decline of 47% is significant compared to industry averages, which typically see growth or modest declines in the e-commerce sector.
• The company's working capital deficit is a concern, as many e-commerce companies maintain a positive working capital position to support growth and operations.
• The company's focus on branded products is similar to other companies like Thrasio and Perch, which acquire and scale e-commerce brands, but Upexi's results indicate challenges in executing this strategy.
• The company's reduction in operating expenses is a positive step, but it needs to be balanced with revenue growth to achieve profitability, which is a common goal for e-commerce businesses.
• The company's internal control weaknesses are a concern, as many public companies in the e-commerce sector have robust internal controls to ensure accurate financial reporting.

Related Party Transactions

• Allan Marshall, the company's CEO, advanced the company $100,000, which was repaid in July 2024.
• The company entered into a lease agreement with MFA 2510 Merchant LLC, owned by CEO Allan Marshall, for a facility in Odessa, Florida.
• Allan Marshall was a minority interest buyer in the sale of VitaMedica, Inc.
• The company has a promissory note with Allan Marshall, which was amended in November 2023.

Stakeholder Impact

• Shareholders are negatively impacted by the decrease in revenue and increase in net loss.
• Employees may be affected by the company's strategic shift and cost-cutting measures.
• Customers may experience changes in product availability and service due to the company's operational changes.
• Suppliers may be impacted by the company's reduced sales and changes in purchasing patterns.
• Creditors may be concerned about the company's working capital deficit and ability to meet debt obligations.

Next Steps

• The company plans to implement the appointment of additional qualified personnel to address inadequate segregation of duties.
• The company plans to implement modifications to its financial controls to address inadequacies.
• The company will continue to monitor and evaluate the effectiveness of its internal controls and procedures and its internal controls over financial reporting on an ongoing basis.

Key Dates

Keywords

revenue, net loss, discontinued operations, working capital, reverse stock split, manufacturing consolidation, branded products, financial results, Upexi, Nasdaq compliance